|
|
IRX-2 |
|
Vaxjo ID |
365 |
|
Vaccine Adjuvant Name |
IRX-2 |
|
Adjuvant VO ID |
VO_0005549
|
|
Description |
multiple cytokine combination adjuvant that induces Th1 response |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
Lot 2050426: IL-1β 0.6 ng/mL, IL-2 5.8 ng/mL, γ-IFN 1.5 ng/mL, TNF-α 1.8 ng/mL, Lot 2007001: IL-1β 0.7 ng/mL, IL-2 6.4 ng/mL, γ-IFN 2.6 ng/mL, TNF-α 2.3 ng/mL, Lot 2007002: IL-1β 0.7 ng/mL, IL-2 5.9 ng/mL, γ-IFN 2.1 ng/mL, TNF-α 1.6 ng/mL |
|
Dosage |
460 units daily (4 injections of 115 units). |
|
Function |
innate immune activation |
| References |
(H. Lee Moffitt Cancer Center, 2025): Clinicaltrials.gov [https://www.clinicaltrials.gov/study/NCT03381183]
Naylor et al., 2010: Naylor PH, Hernandez KE, Nixon AE, Brandwein HJ, Haas GP, Wang CY, Hadden JW. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. Vaccine. 2010; 28(43); 7054-7062. [PubMed: 20708999].
Wolf et al., 2011: Wolf GT, Fee WE Jr, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR, Gillespie MB, Freeman SM, Baltzer L, Kirkley TD, Brandwein HJ, Hadden JW. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head & neck. 2011; 33(12); 1666-1674. [PubMed: 21284052].
|
|
